| URL | http://www.reuters.com/article/us-india-pharma-usa |
| Source | Reuters |
| Date Published | 02/10/2017 |
| Author Name | Zeba Siddiqui |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Aurobindo |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2017 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | India |
| City reshored to: | Dayton |
| State(s) reshored to: | NJ |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | injectables |
| What non-domestic negative factors made offshoring less attractive? | Tariffs |
| What domestic positive factors made reshoring more attractive? | , Trump? |